Trump nominates Chris Klomp as HHS second-in-command

Trump Nominates Chris Klomp as HHS Second-in-Command

Trump nominates Chris Klomp as HHS second – President Donald Trump announced on Thursday the appointment of Chris Klomp to the position of deputy secretary at the U.S. Department of Health and Human Services (HHS). Klomp, who has served as the director of Medicare since April 2025, will now hold a pivotal role in overseeing the agency’s operational functions and shaping regulatory strategies. This decision marks a strategic shift within the administration, positioning Klomp as the second-highest-ranking official under Secretary Robert F. Kennedy Jr., who has been a key figure in Trump’s healthcare agenda for several months.

A Focus on Efficiency and Leadership

Klomp’s new role is expected to centralize efforts to streamline HHS operations and advance policies aligned with Trump’s vision for cost-effective healthcare solutions. His confirmation by the Senate will add him to the list of federal health nominees awaiting hearings before the Senate Health, Education, Labor and Pensions Committee. The move comes as a continuation of the administration’s broader initiative to refocus healthcare messaging on reducing expenses and promoting the TrumpRx program, which aims to lower prescription drug prices for Americans.

“HHS is a massive and complex organization, but Chris knows exactly how to run it,” Trump stated on Truth Social. He emphasized that the selection of Klomp was a collaborative effort among himself, Kennedy, and Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz.

Klomp’s tenure as Medicare director has already positioned him as a central figure in the administration’s efforts to negotiate with pharmaceutical companies. His leadership was instrumental in brokering deals under the TrumpRx initiative, which seeks to reduce healthcare costs by leveraging the most-favored nations plan. This strategy aims to cut prescription drug prices by comparing them to those in other countries, a tactic that has drawn both support and scrutiny from critics and allies alike.

Leadership Vacancy and Strategic Reorganization

The HHS has been without a deputy secretary since Jim O’Neill departed in February 2026, following a leadership reorganization that reshaped the agency’s structure. This change was intended to enhance efficiency and ensure a cohesive approach to Trump’s healthcare priorities, including cost reduction and regulatory reform. Klomp’s appointment fills this critical role, allowing him to provide direct guidance to Kennedy while managing the day-to-day operations of the department.

Klomp’s responsibilities as Medicare director have expanded beyond managing the program’s budget and services. He has been deeply involved in shaping the administration’s messaging around healthcare affordability, working closely with Kennedy to highlight progress on initiatives like the TrumpRx program. His ability to communicate effectively with stakeholders, including lawmakers and industry leaders, has been a key asset in advancing these policies.

“Chris Klomp has been unbelievable, a real star,” Trump remarked during a White House event in April 2026, celebrating a landmark agreement with drugmaker Regeneron. “You don’t know his name as much as some of the others, but he’s a real star of the group.”

Trump’s praise for Klomp underscores the significance of his contributions to the administration’s healthcare strategy. As Medicare director, Klomp has also played a vital role in leading internal efforts to identify qualified candidates for other high-profile positions within HHS. This year, he oversaw the search for a new leader at the Centers for Disease Control and Prevention (CDC) and the surgeon general’s office, resulting in the nomination of public health veteran Dr. Erica Schwartz for CDC director and Fox News contributor Dr. Nicole Saphier for surgeon general. Both nominees are currently awaiting Senate confirmation hearings.

Additionally, Klomp has been central to the process of selecting a replacement for former U.S. Food and Drug Administration (FDA) Commissioner Dr. Marty Makary, who resigned in May 2026. His involvement in this search reflects his growing influence within the administration’s health policy framework. Critics have noted that Klomp’s appointment signals a broader consolidation of power under Kennedy, who has been a prominent voice in shaping the department’s direction.

Public Health and Policy Challenges

The HHS’s reorganization has placed Klomp in a position to address pressing public health challenges, including the management of the CDC and the FDA. With the Trump administration prioritizing deregulation and market-driven reforms, Klomp’s leadership is expected to balance these goals with the need for robust regulatory oversight. His experience in Medicare administration, where he has demonstrated a knack for managing large-scale programs, positions him well to handle the complexities of the department’s operations.

Klomp’s nomination also highlights the administration’s focus on maintaining continuity in key healthcare initiatives. By appointing someone with a proven track record in implementing policies that align with Trump’s vision, the White House aims to ensure stability and momentum in its efforts to lower healthcare costs. His role as deputy secretary will involve coordinating with various federal agencies to further these objectives, particularly as the TrumpRx program faces ongoing debates in Congress.

Political and Professional Implications

The selection of Klomp has sparked discussions about the political dynamics within the HHS. While his background as a former health care executive lends credibility to his ability to manage the agency, his close relationship with Kennedy raises questions about the distribution of influence within the administration. Klomp’s confirmation process will likely be scrutinized by Senate committees, with lawmakers weighing his qualifications against the broader goals of the Trump administration.

As the HHS continues to navigate its role in the new political landscape, Klomp’s appointment represents a significant step in the administration’s strategy to maintain control over healthcare policy. His work in Medicare has already demonstrated a commitment to operational excellence, and his transition to deputy secretary is seen as a logical progression in his career. The White House has expressed confidence in his ability to lead the department through its evolving priorities, from pharmaceutical cost reduction to public health preparedness.

With the Senate confirmation process underway, Klomp’s role as deputy secretary is set to play a critical part in shaping the future of U.S. healthcare. His leadership will be tested as the administration seeks to implement its ambitious plans while addressing challenges such as rising prescription costs and the complexities of regulatory reform. As the confirmation hearings proceed, the broader implications of this appointment for the HHS and the nation’s healthcare system will become more apparent.